Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in Seasonal Allergic Rhinitis – Phase II Safety Study
CTR20231682Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Keymed Biosciences. Primary endpoint: Adverse events, laboratory tests, physical examination, vital signs, and 12-lead ECG abnormalities. Started Jun 2023; status: completed.
02
Drugs
stapokibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20231682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231682.